• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by ACELYRIN INC.

    2/14/25 6:13:35 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    ACELYRIN, Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share (the "Shares")

    (Title of Class of Securities)


    00445A100

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00445A100


    1Names of Reporting Persons

    Citadel Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,192,377.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,192,377.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,192,377.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    IA, HC, OO

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 100,325,569 Shares outstanding as of November 8, 2024 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on November 13, 2024).


    SCHEDULE 13G

    CUSIP No.
    00445A100


    1Names of Reporting Persons

    Citadel Advisors Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,192,377.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,192,377.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,192,377.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    00445A100


    1Names of Reporting Persons

    Citadel GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,192,377.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,192,377.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,192,377.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    00445A100


    1Names of Reporting Persons

    Citadel Securities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,832.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,832.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,832.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    BD, OO


    SCHEDULE 13G

    CUSIP No.
    00445A100


    1Names of Reporting Persons

    Citadel Securities Group LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    26,371.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    26,371.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    26,371.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    00445A100


    1Names of Reporting Persons

    Citadel Securities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    26,371.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    26,371.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    26,371.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    00445A100


    1Names of Reporting Persons

    Kenneth Griffin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,218,748.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,218,748.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,218,748.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ACELYRIN, Inc.
    (b)Address of issuer's principal executive offices:

    4149 Liberty Canyon Road Agoura Hills, CALIFORNIA, 91301
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company ("CM"), CRBU Holdings LLC, a Delaware limited liability company ("CRBH"), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares. Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of CRBH and Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
    (b)Address or principal business office or, if none, residence:

    The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
    (c)Citizenship:

    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share (the "Shares")
    (e)CUSIP No.:

    00445A100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 4,192,377 Shares. 2. Citadel Securities LLC may be deemed to beneficially own 6,832 Shares. 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 26,371 Shares. 4. Mr. Griffin may be deemed to beneficially own 4,218,748 Shares.
    (b)Percent of class:

    1. The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 4.2% of the Shares outstanding. 2. The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding. 3. The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding. 4. The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 4.2% of the Shares outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (ii) Shared power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 4,192,377 2. Citadel Securities LLC: 6,832 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 26,371 4. Mr. Griffin: 4,218,748

     (iii) Sole power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (iv) Shared power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 4,192,377 2. Citadel Securities LLC: 6,832 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 26,371 4. Mr. Griffin: 4,218,748

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Citadel Advisors LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:02/14/2025
     
    Citadel Advisors Holdings LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:02/14/2025
     
    Citadel GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:02/14/2025
     
    Citadel Securities LLC
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:02/14/2025
     
    Citadel Securities Group LP
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:02/14/2025
     
    Citadel Securities GP LLC
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:02/14/2025
     
    Kenneth Griffin
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, attorney-in-fact*
    Date:02/14/2025

    Comments accompanying signature:  * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
    Get the next $SLRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLRN

    DatePrice TargetRatingAnalyst
    8/14/2024$18.00 → $6.00Buy → Neutral
    H.C. Wainwright
    7/8/2024$13.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$11.00Equal Weight
    Wells Fargo
    12/8/2023$8.00Neutral
    Citigroup
    9/13/2023$19.00Overweight → Equal-Weight
    Morgan Stanley
    9/5/2023$44.00Buy
    H.C. Wainwright
    5/30/2023Overweight
    Morgan Stanley
    5/30/2023$31.00Buy
    Jefferies
    More analyst ratings

    $SLRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ayurmaya Capital Management Company, Lp returned 9,334,735 shares to the company (SEC Form 4)

    4 - ACELYRIN, Inc. (0001962918) (Issuer)

    5/23/25 4:23:20 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kim Mina was granted 89,526 shares and returned 770,833 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ACELYRIN, Inc. (0001962918) (Issuer)

    5/23/25 4:11:54 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cozadd Bruce C

    4 - ACELYRIN, Inc. (0001962918) (Issuer)

    5/23/25 4:11:07 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ACELYRIN downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded ACELYRIN from Buy to Neutral and set a new price target of $6.00 from $18.00 previously

    8/14/24 7:48:43 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded ACELYRIN from Equal Weight to Overweight and set a new price target of $13.00

    7/8/24 8:17:02 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on ACELYRIN with a new price target

    Wells Fargo initiated coverage of ACELYRIN with a rating of Equal Weight and set a new price target of $11.00

    12/13/23 8:08:18 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alumis Stockholders Approve Merger with ACELYRIN

    SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:SLRN) at its Special Meeting of Stockholders. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditious

    5/13/25 1:00:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

    LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. "We appreciate our stockholders' support for our merger

    5/13/25 1:00:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

    ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that ACELYRIN stockholders vote "FOR" the proposed merger ("Proposed Transaction") of the Company with Alumis Inc. (NASDAQ:ALMS). The Company's special meeting of stockholders to vote on the Proposed Transaction is scheduled for May 13, 2025. ACELYRIN urges its stockholders to vote FOR the Pr

    5/6/25 4:30:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

    SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

    5/23/25 4:15:26 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

    SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

    5/23/25 4:01:03 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by ACELYRIN INC.

    EFFECT - ACELYRIN, Inc. (0001962918) (Filer)

    5/23/25 12:15:04 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Financials

    Live finance-specific insights

    View All

    ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

    LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan ("Rights Plan"). The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value. Pursuant to the Rights Plan, the Company is issuing one right for each share of common stock as of the close

    3/13/25 7:00:00 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

    Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

    2/6/25 4:15:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

    Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery

    1/6/25 4:00:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

    Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava

    3/27/24 4:01:00 PM ET
    $AVTX
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

    Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company's Senior Leadership Team.

    2/15/24 4:05:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

    LOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors. "I am pleased to welcome Lynn to our board of directors as we close our first year as a publicly traded company. Lynn is a highly accomplished biopharma executive and her extensive expertise spanning global human capital strategy, talent management, business operations, and corporate affairs adds a valuable dimension to support our evolving company," said Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN

    12/20/23 4:30:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

    SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

    11/14/24 1:28:35 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

    SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

    11/12/24 12:13:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ACELYRIN INC.

    SC 13G - ACELYRIN, Inc. (0001962918) (Subject)

    11/4/24 10:56:23 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care